@Hans_BMTProgram

Official account of the Hans Messner Allogeneic Blood and Marrow Transplant Program at Princess Margaret Hospital, Toronto. Posts are not medical advice.

 Toronto
uhn.ca/PrincessMargaret/Clinics/Allogeneic_Transplant
Joined March 2020
  • Tweets144
  • Following123
  • Followers198
32Media
Replying to @Hans_BMTProgram
Our multidisciplinary team endeavours to provide the highest standards of care. The overarching theme that drives our efforts are to get patients back to their normal lives by treating their diseases, limiting complications (NRM), and preserving quality of life (GRFS).
1
2
4
1,845
Hans Messner Allogeneic BMT Program retweeted
Shernan Holtan MD
@sghmdOct 3
Swiss cheese ๐Ÿง€ model of why PTCy + ATG may be complementary, not redundant. @nihardesai89 emphasized lower dose ATG is key. ๐Ÿ”‘ @COSTEMCongress @Hans_BMTProgram
2
8
36
1,947
Tomorrow at Monthly Fellows Rounds: Guest speaker Welaia Alsaffar (@welaia_ali) presents: โ€œWho Is the Best Donor? Revisiting the Hierarchy of Donor Selectionโ€ ๐Ÿ“… Wed, Aug 26 ๐Ÿ•› 12:00 pm ๐Ÿ’ป MS Teams @pmcancercentre @PMResearch_UHN
1
2
2
223
Excellent presentation by Welaia Alsaffar (@welaia_ali): the โ€œbest donorโ€ in allo-HCT is not defined by a fixed hierarchy. Disease, urgency and platform matter; HLA match and DSA remain central, with age, CMV status and availability refining the choice.
2
2
111
Tomorrow morning at our Malignant Hematology Education Round: ๐Ÿงฌ Dr Dennis Kim: Post-EHA learnings ๐ŸŽฏ Mohamed Sharif, Clinical Fellow: โ€œRemission Is Not the Finish Lineโ€ Wed Aug 26 | 8:00-9:00 am Hybrid: OPG + MS Teams @pmcancercentre @PMResearch_UHN
1
1
140
Tomorrow, Fri 21 Aug | Hans Messner Allogeneic BMT Academic Activity Rounds ๐Ÿงฌ Dr. Frank Michelis (@FotiosMichelis): second malignancies after allogeneic SCT ๐Ÿšญ Dr. Ebaa Reda, Clinical Fellow: prior smoking history and post-allo-HCT outcomes @pmcancercentre @PMResearch_UHN
1
2
169
Invitation-only โญ Our 4th Annual Allogeneic BMT Patient Survivorship Day celebrates BMT survivors, their invited caregivers/family members and the BMT team. ๐Ÿ“… 20 Sept 2026, 1โ€“4 pm | Vaughan ๐Ÿ“ŒPrivate event for invited attendees. @pmcancercentre @UHN
1
2
2
154
Invited attendees: please RSVP by Friday, 11 Sept to [email protected]
23
๐Ÿ“ข Now out in @BrJHaem ๐ŸŽŠ๐ŸŽ‰ Our latest work from the @pmcancercentre explores how GvHD prophylaxis influences the risk of second primary malignancies after allogeneic transplants using a large cohort of 1,418 patients (>6000 person-years of follow up) onlinelibrary.wiley.com/doi/โ€ฆ
4
16
1
57
6,126
๐Ÿ“ข Published in @ASTCT_Journal ๐ŸŽ‰ Using a large dataset (@CIBMTR + @Hans_BMTProgram), we show that ATG + PTCy may alleviate the โคด๏ธGvHD risk associated with female donor-to-male recipient MUD transplants ๐Ÿ™Œ๐Ÿฝ astctjournal.org/article/S26โ€ฆ
5
14
3
80
7,736
๐ŸŽ‰ Out now in @ASTCT_Journal ๐Ÿ™Œ๐Ÿฝ We compare two conditioning regimens for second allogeneic transplant after primary graft failure! Interesting results ๐Ÿ‘‡๐Ÿฝ DM me for the PDF! sciencedirect.com/science/arโ€ฆ @Hans_BMTProgram
2
17
68
4,745
Hans Messner Allogeneic BMT Program retweeted
Ahmed AlNughmush@AhmedAlNughmush13 Jun 2025
Our work is now out in @ASTCT_Journal We looked into the association between cumulative cyclosporine exposure over the first 90 days (AUC90) post-HCT and key transplant outcomes, including graft failure and relapse. @Hans_BMTProgram astctjournal.org/article/S26โ€ฆ
1
4
10
902
Delighted to share our latest publication on the impact of conditioning intensity in younger AML patients receiving dual T-cell depletion for GVHD prophylaxis. #Hematology #BMT @AhmedAlNughmush @Hans_BMTProgram doi.org/10.1111/ejh.14438

Impact of Conditioning Intensity on Survival in Adult Patients (<โ€‰65โ€‰Years) With Acute Myeloid...

Introduction Myeloablative conditioning (MAC) for acute myeloid leukemia (AML) improves disease control by reducing relapse risk but is associated with higher non-relapse mortality (NRM). Reduced-i...

onlinelibrary.wiley.com
1
6
23
2,284
Hans Messner Allogeneic BMT Program retweeted
Arjun D. Law@Haemophage22 May 2025
Proud moment at the CTTC Conference! Hereโ€™s a roundup of phenomenal poster presentations from our team at @Hans_BMTProgram @UHN and @pmcancercentre , tackling real-world challenges in transplant medicine and GVHD. #CTTC2025 #HCT #GVHD #HemeTwitter 1/10
1
4
13
1,204
๐Ÿšจ New Study Alert! @nihardesai89 @Haemophage @IvanPasic Our team retrospectively analyzed our cohort on allogeneic HSCT outcomes in patients with MDS/MPN overlap syndromesโ€”a rare and challenging group of hematologic neoplasms. ๐Ÿงต๐Ÿ‘‡
2
7
1
22
5,201
Excellent thread summarising key findings of our latest publication from @pmcancercentre ๐Ÿ‘‡๐Ÿฝ DM me if you want the PDF ๐Ÿ™Œ๐Ÿฝ onlinelibrary.wiley.com/doi/โ€ฆ #MedTwitter @SergioRdzRdz @Hans_BMTProgram @Haemophage
Sergio Rodrรญguez-Rodriguez, MD, MSc. ๐Ÿ‡ฒ๐Ÿ‡ฝ@SergioRdzRdz18 May 2025
๐Ÿšจ New Study Alert! @nihardesai89 @Haemophage @IvanPasic Our team retrospectively analyzed our cohort on allogeneic HSCT outcomes in patients with MDS/MPN overlap syndromesโ€”a rare and challenging group of hematologic neoplasms. ๐Ÿงต๐Ÿ‘‡
3
8
1
40
4,069
The abstract titles for #ASCO25 are out ๐Ÿ™Œ๐Ÿฝ We asked 2 questions: 1. Can we โคต๏ธthe PTCy dose in MUDs? 2. What's the outcome of patients who are alive 2 yr post transplant? We'll answer those questions at the oral abstract session @ASCO #MedTwitter @Hans_BMTProgram
4
10
1
46
5,118
Hans Messner Allogeneic BMT Program retweeted
Princess Margaret Cancer Centre@pmcancercentre27 Mar 2025
Exciting news from a dear patient. Thank you for sharing your journey with us.
FergDevins
@FergDevins27 Mar 2025
After 4 weeks in @pmcancercentre @UHN and 21 days post stem cell transplant from my sister, I am discharged to home and now an out-patient. Excellent care - the recovery journey continues - sincere thanks to family and friends for your ongoing love and support
3
3
14
1,882
Load more